Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

ISARIC Clinical Characterisation Group

Producción científica: RevistaArtículorevisión exhaustiva

47 Citas (Scopus)

Resumen

Background: We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world’s largest international, standardized data sets concerning hospitalized patients. Methods: The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV). Results: Data were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60 years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5%. Conclusions: Age was the strongest determinant of risk of death, with a ~30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death. The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death.

Idioma originalInglés
Páginas (desde-hasta)355-376
Número de páginas22
PublicaciónInternational Journal of Epidemiology
Volumen52
N.º2
DOI
EstadoPublicada - 1 abr. 2023

Nota bibliográfica

Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press on behalf of the International Epidemiological Association.

Financiación

FinanciadoresNúmero del financiador
European Clinical Research Alliance on Infectious Diseases
Sunnybrook Research Institute
Seventh Framework Programme
Ministerio de Ciencia
Instituto de Salud Carlos III
Institut national de la santé et de la recherche médicale
Artificial Intelligence for Pandemics
Italian Ministry of Health ‘Fondi Ricerca corrente
Prince Charles Hospital Foundation
South Eastern Norway Health Authority and the Research Council of Norway
Groote Schuur Hospital Covid ICU Team
COVID-19 Clinical Management team
National Institute for Health Research Health Protection Research Unit
University of Queensland
Manipal Hospital Whitefield
foundation Bevordering Onderzoek Franciscus
University of Cape Town
Firland Foundation
Manchester Biomedical Research Centre
University of Oxford
HPRU
Bill and Melinda Gates FoundationOPP1209135
Conselho Nacional de Desenvolvimento Científico e Tecnológico303953/2018–7
Liverpool Experimental Cancer Medicine CentreC18616/A25153
Horizon 2020 Framework Programme965313, 101003589
Public Health England200907
Imperial College London200927
National Institute for Health and Care ResearchCO-CIN-01
Wellcome Trust220757, 220757/Z/20/Z, 215091/Z/18/Z, 205228/Z/16/ Z, 205228
Stiftungsfonds zur Förderung der Bekämpfung der Tuberkulose und anderer Lungenkrankheiten of the City of ViennaAPCOV22BGM
Biotechnology and Biological Sciences Research CouncilBBS/E/RL/230002D
Australian Department of Health3273191
Norges ForskningsrådNIHR201385, 312780
European Federation of Pharmaceutical Industries and AssociationsNCT04262921
Innovative Medicines Initiative115523
NIHR Biomedical Research Centre at Imperial College LondonIS-BRC-1215–20013
Canadian Institutes of Health ResearchOV2170359
Ministère des Affaires Sociales et de la SantéPHRC n 20–0424
UK Research and InnovationMC_PC_19059
Health Research BoardCTN-2014–12
Australian Research CouncilCE170100009
Medical Research CouncilMR/V001671/1

    Huella

    Profundice en los temas de investigación de 'Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19'. En conjunto forman una huella única.

    Citar esto